GlassScriptPhysician profile
Hazel F Mitchell
NPI 1235545658
$3,080.33
in general payments reported to CMS, 2019-2025
29 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $163 · 2023: $616 · 2024: $933 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,672.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $602.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $536.35 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $341.02 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $320.18 | 2023-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $165.02 | 2023-2025 | |
| Glaxosmithkline, LLC. | $149.48 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $110.47 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $93.07 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $92.40 | 2024-2025 | Voquezna |
| Abbott Laboratories | $80.25 | 2021-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.08 | 2023-2025 | Jardiance, Synjardy |
| Verona Pharma, INC. | $59.83 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.08 | 2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.81 | 2025 | Caplyta |
| Amarin Pharma, INC. | $35.55 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $34.54 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $34.10 | 2021 | |
| Amgen INC. | $30.58 | 2025 | Repatha, Otezla |
| Viiv Healthcare Company | $29.36 | 2024 | Apretude |
| Gilead Sciences, INC. | $26.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.09 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.77 | 2023 | Abilify Asimtufii, Rexulti |
| Mylan Specialty L.P. | $21.59 | 2023 | Yupelri |
| Dexcom, INC. | $21.52 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $18.09 | 2025 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $17.19 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.66 | 2022 | |
| Cvrx, INC. | $12.04 | 2025 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazel Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.